DOI QR코드

DOI QR Code

Noninvasive Detection of Specific Diagnostic Biomarkers for Atopic Dermatitis

  • Chang, Jeong Hyun (Department of Clinical Laboratory Science, Daegu Haany University)
  • Received : 2019.01.28
  • Accepted : 2019.03.14
  • Published : 2019.03.31

Abstract

The diagnosis of atopic dermatitis (AD) includes a test that checks allergen-mediated skin reactions and a method of measuring the total IgE and allergen-specific IgE in blood. However, these test methods are performed directly on the patient, which cause some pain or discomfort. In addition, the skin response test or IgE may result in false negative in about 20% of patients. In the present study, to identify specific biomarkers, HaCaT cells were used as a human keratinocyte that make up the skin, were treated IL-4 and IL-13 for 24 hours to induce a situation similar to keratinocytes in AD patients. In the HaCaT cells, pro-inflammatory cytokine such as IL-5, IL-6, and MCP-1 were increased by IL-4 and IL-13 and skin barrier proteins was reduced by IL-4 and L-13. This results showed that a situation similar to the stratum corneum of an actual patient is induced in HaCaT cells. And then the secretions of Kallikrein (KLK) 5 and KLK7 protease were checked by enzyme-linked immunosorbent assay (ELISA). It was specifically increased by IL-4 and IL-13. This showed that AD-related protease can be detected at the protein level using keratinocytes that can be taken in a non-invasive manner and suggested the possibility of applying it to AD diagnosis.

Keywords

References

  1. Bennett K, Callard R, Heywood W, Harper J, Jayakumar A, Clayman GL, Di WL, Mills K. New role for LEKTI in skin barrier formation: label-free quantitative proteomic identification of caspase 14 as a novel target for the protease inhibitor LEKTI. Journal of Proteome Research. 2010. 9: 4289-4294. https://doi.org/10.1021/pr1003467
  2. Boguniewicz M, Leung DY. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunological Reviews. 2011. 242: 233-246. https://doi.org/10.1111/j.1600-065X.2011.01027.x
  3. Boguniewicz M, Schmid-Grendelmeier P, Leung DY. Atopic dermatitis. Journal of Allergy and Clinical Immunology. 2006. 118: 40-43. https://doi.org/10.1016/j.jaci.2006.04.044
  4. Cork MJ, Danby SG, Vasilopoulos Y, Hadgraft J, Lane ME, Moustafa M, Guy RH, Macgowan AL, Tazi-Ahnini R, Ward SJ. Epidermal barrier dysfunction in atopic dermatitis. Journal of Investigative Dermatology. 2009. 129: 1892-1908. https://doi.org/10.1038/jid.2009.133
  5. Di ZH, Ma L, Qi RQ, Sun XD, Huo W, Zhang L, Lyu YN, Hong YX, Chen HD, Gao XH. T Helper 1 and T Helper 2 Cytokines Differentially Modulate Expression of Filaggrin and its Processing Proteases in Human Keratinocytes. Chinese Medical Journal. 2016. 129: 295-303. https://doi.org/10.4103/0366-6999.174489
  6. Eichenfield LF, Tom WL, Chamlin SL, Feldman SR, Hanifin JM, Simpson EL, Berger TG, Bergman JN, Cohen DE, Cooper KD, Cordoro KM, Davis DM, Krol A, Margolis DJ, Paller AS, Schwarzenberger K, Silverman RA, Williams HC, Elmets CA, Block J, Harrod CG, Smith Begolka W, Sidbury R. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. Journal of the American Academy of Dermatology. 2014. 70: 338-351. https://doi.org/10.1016/j.jaad.2013.10.010
  7. Ekanayake-Mudiyanselage S, Aschauer H, Schmook FP, Jensen JM, Meingassner JG, Proksch E. Expression of epidermal keratins and the cornified envelope protein involucrin is influenced by permeability barrier disruption. Journal of Investigative Dermatology. 1998. 111: 517-523. https://doi.org/10.1046/j.1523-1747.1998.00318.x
  8. Komatsu N, Saijoh K, Kuk C, Liu AC, Khan S, Shirasaki F, Takehara K, Diamandis EP. Human tissue kallikrein expression in the stratum corneum and serum of atopic dermatitis patients. Experimental Dermatology. 2007. 16: 513-519. https://doi.org/10.1111/j.1600-0625.2007.00562.x
  9. Komatsu N, Saijoh K, Toyama T, Ohka R, Otsuki N, Hussack G, Takehara K, Diamandis EP. Multiple tissue kallikrein mRNA and protein expression in normal skin and skin diseases. British Journal of Dermatology. 2005. 153: 274-281. https://doi.org/10.1111/j.1365-2133.2005.06754.x
  10. Kuo IH, Yoshida T, De Benedetto A, Beck LA. The cutaneous innate immune response in patients with atopic dermatitis. Journal of Allergy and Clinical Immunology. 2013. 131: 266-278. https://doi.org/10.1016/j.jaci.2012.12.1563
  11. Leung DY, Boguniewicz M, Howell MD, Nomura I, Hamid QA. New insights into atopic dermatitis. Journal of Clinical Investigation. 2004. 113: 651-657. https://doi.org/10.1172/JCI21060
  12. Leung DY. Pathogenesis of atopic dermatitis. Journal of Allergy and Clinical Immunology. 1999. 104: S99-108. https://doi.org/10.1016/S0091-6749(99)70051-5
  13. Liu FT, Goodarzi H, Chen HY. IgE, mast cells, and eosinophils in atopic dermatitis. Clinical Reviews in Allergy & Immunology. 2011. 41: 298-310. https://doi.org/10.1007/s12016-011-8252-4
  14. Meng X, Qiu L, Song H, Dang N. MAPK Pathway Involved in Epidermal Terminal Differentiation of Normal Human Epidermal Keratinocytes. Open Medicine. 2018. 10: 189-195. https://doi.org/10.1515/med-2018-0029
  15. Meyer-Hoffert U. Reddish, scaly, and itchy: how proteases and their inhibitors contribute to inflammatory skin diseases. Archivum Immunologiae et Therapia Experimentalis. 2009. 57: 345-354. https://doi.org/10.1007/s00005-009-0045-6
  16. Omori-Miyake M, Yamashita M, Tsunemi Y, Kawashima M, Yagi J. In vitro assessment of IL-4- or IL-13-mediated changes in the structural components of keratinocytes in mice and humans. Journal of Investigative Dermatology. 2014. 134: 1342-1350. https://doi.org/10.1038/jid.2013.503
  17. O'Regan GM, Sandilands A, McLean WHI, Irvine AD. Filaggrin in atopic dermatitis. Journal of Allergy and Clinical Immunology. 2008. 122: 689-693. https://doi.org/10.1016/j.jaci.2008.08.002
  18. Ovaere P, Lippens S, Vandenabeele P, Declercq W. The emerging roles of serine protease cascades in the epidermis. Trends in Biochemical Sciences. 2009. 34: 453-463. https://doi.org/10.1016/j.tibs.2009.08.001
  19. Pastore S, Mascia F, Giustizieri ML, Giannetti A, Girolomoni G. Pathogenetic mechanisms of atopic dermatitis. Archivum Immunologiae et Therapia Experimentalis. 2000. 48: 497-504.
  20. Salkie ML. Role of clinical laboratory in allergy testing. Clinical Biochemistry. 1994. 27: 343-355. https://doi.org/10.1016/0009-9120(94)90038-8
  21. Sandilands A, Sutherland C, Irvine AD, McLean WH. Filaggrin in the frontline: role in skin barrier function and disease. Journal of Cell Science. 2009. 122: 1285-1294. https://doi.org/10.1242/jcs.033969
  22. Seguchi T, Cui CY, Kusuda S, Takahashi M, Aisu K, Tezuka T. Decreased expression of filaggrin in atopic skin. Archives of Dermatological Research. 1996. 288: 442-446. https://doi.org/10.1007/BF02505232
  23. Shimada Y, Takehara K, Sato S. Both Th2 and Th1 chemokines (TARC/CCL17, MDC/CCL22, and Mig/CXCL9) are elevated in sera from patients with atopic dermatitis. Journal of Dermatological Science. 2004. 34: 201-208. https://doi.org/10.1016/j.jdermsci.2004.01.001